Prognostic value of clinicopathological parameters in adenoid cystic carcinoma: A retrospective cohort study

Table 4 Clinical-outcome correlations, n (%)/mean ± SD

Variable	Recurrence (n = 16)	No recurrence (n = 39)	P value	Deaths (n = 24)	Alive (n = 31)	P value
Age (years)	61.3 ± 11.9	59.8 ± 12.4	0.44	57.8 ± 14.0	60.8 ± 12.5	0.37
Sex
Male (n = 20)	6 (30.0)	14 (70.0)	0.61	9 (45.0)	11 (55.0)	0.58
Female (n = 35)	10 (28.6)	25 (71.4)		14 (40.0)	21 (60.0)
Margins
R0 (n = 38)	8 (21.1)	30 (78.9)	0.038	12 (31.6)	26 (68.4)	0.033
R1/R2 (n = 17)	8 (47.1)	9 (52.9)		11 (64.7)	6 (35.3)
Perineural invasion
Absent (n = 13)	2 (15.4)	11 (84.6)	0.041	3 (23.1)	10 (76.9)	0.026
Present (n = 42)	14 (33.3)	28 (66.7)		20 (47.6)	22 (52.4)
T stage
T1 and T2 (n = 23)	4 (17.4)	19 (82.6)	0.029	6 (26.1)	17 (73.9)	0.018
T3 and T4 (n = 32)	12 (37.5)	20 (62.5)		17 (53.1)	15 (46.9)
N stage
N0 (n = 40)	10 (25.0)	30 (75.0)	0.21	15 (37.5)	25 (62.5)	0.24
N+ (n = 15)	6 (40.0)	9 (60.0)		8 (53.3)	7 (46.7)
M stage
M0 (n = 49)	13 (26.5)	36 (73.5)	0.17	19 (38.8)	30 (61.2)	0.14
M1 (n = 6)	3 (50.0)	3 (50.0)		4 (66.7)	2 (33.3)
Postoperative radiotherapy
Yes (n = 34)	7 (20.6)	27 (79.4)	0.031	11 (32.4)	23 (67.6)	0.040
No (n = 21)	9 (42.9)	12 (57.1)		12 (57.1)	9 (42.9)
Chemotherapy
Yes (n = 5)	2 (40.0)	3 (60.0)	0.48	3 (60.0)	2 (40.0)	0.51
No (n = 50)	14 (28.0)	36 (72.0)		20 (40.0)	30 (60.0)